The interest in blocking tau aggregation in neurons, in a subset of neurodegenerative diseases commonly referred to as tauopathies, including the most prevalent Alzheimer’s disease, led to the optimization of VHH E4-1 for intracellular use, resulting in the selection of VHH Z70. The gene discussed is MAPT; the disease is neurodegenerative disease.